Study guide
13.2 Bioethics, Informed Consent & Quality Improvement in Oncology
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
13.2 Bioethics, Informed Consent & Quality Improvement in Oncology
Key Takeaways Explain This Topic AI
The four foundational principles of biomedical ethics (Autonomy, Beneficence, Non-maleficence, Justice) guide complex oncology decision-making and palliative transitions.
The Belmont Report establishes ethical standards for human subjects research based on Respect for Persons, Beneficence, and Justice, enforced by Institutional Review Boards (IRBs).
Clinical trial IRB review levels are categorized into Exempt, Expedited, and Full Board Review based on potential patient risk.
ASCO Quality Oncology Practice Initiative (QOPI) and NCCN metrics evaluate clinical performance across staging, biomarker testing, and symptom management.
Root Cause Analysis (RCA) uses 5 Whys and Fishbone diagrams to investigate adverse events by identifying latent systemic flaws rather than assigning individual fault.
Last updated: August 2026
9.2 Bioethics, Informed Consent & Quality Improvement in Oncology
Advanced Practice Registered Nurses (APRNs) in oncology routinely navigate challenging bioethical dilemmas, clinical trial protocols, and quality improvement initiatives. Ensuring patient self-determination, ethical research conduct, and robust quality measures is essential for delivery of safe, equitable cancer care.
The Four Core Principles of Biomedical Ethics
Oncology practice involves high-stakes decision-making regarding aggressive antineoplastic therapy, phase I clinical trial participation, and end-of-life care. The classic Beauchamp and Childress bioethical framework outlines four primary principles :
1. Autonomy
Autonomy recognizes the moral right of competent individuals to make self-determining healthcare decisions. In oncology, this principle underlies informed consent , the right to refuse chemotherapy or radiation, advance directive execution, and appointment of a surrogate decision-maker (Durable Power of Attorney for Healthcare). APRNs must ensure patients receive unbiased, comprehensive disclosures regarding disease prognosis, treatment goals, and risk profiles free from coercion.
2. Beneficence
Beneficence imposes an affirmative duty on healthcare providers to act in the best interest of the patient. In oncology, beneficence involves recommending evidence-based antineoplastic treatments to achieve disease remission, palliate debilitating cancer symptoms, and optimize quality of life.
3. Non-Maleficence
Non-maleficence dictates "first, do no harm" ( primum non nocere ). Because virtually all antineoplastic agents carry significant toxicity (e.g., myelosuppression, cardiotoxicity, neurotoxicity), APRNs must carefully weigh potential therapeutic gains against treatment burdens. Withdrawing futile, toxic chemotherapy when risks far outweigh clinical benefit aligns directly with non-maleficence.
4. Justice
Justice demands fair, equitable distribution of healthcare resources and equal access to clinical trials, cancer screening, and novel targeted therapies regardless of socioeconomic status, race, or geographic location.
Clinical Research Ethics & The Belmont Report
All human subjects research in oncology must comply with federal regulations (Common Rule / 45 CFR 46) rooted in The Belmont Report (1979) . The report establishes three overarching ethical principles for human research:
Respect for Persons : Asserts that individuals are autonomous agents and requires special protection for vulnerable populations (e.g., pediatric patients, cognitively impaired individuals, prisoners, economically disadvantaged persons). It forms the foundation for voluntary informed consent.
Beneficence : Mandates maximizing potential benefits while minimizing potential risks to research participants.
Justice : Requires equitable selection of research subjects so that no single demographic group bears unfair research burdens or is denied potential trial benefits.
Institutional Review Board (IRB) Oversight & Review Levels
Every clinical research protocol must receive approval from an Institutional Review Board (IRB) prior to study activation. IRBs categorize protocol reviews into three distinct risk tiers:
IRB Review Level Risk Threshold Protocol Criteria & Oncology Examples
Exempt Review Less than minimal risk De-identified retrospective medical chart reviews, secondary data analysis, or educational assessments where subject identities cannot be linked.
Expedited Review Minimal risk (risk not greater than routine physical/psychological exams) Non-invasive specimen collection (e.g., routine phlebotomy, saliva), non-invasive diagnostic imaging without contrast, or low-risk survey studies.
Full Board Review Greater than minimal risk Interventional clinical trials evaluating investigational drugs, Phase I-III novel immunotherapy/chemotherapy trials, or invasive interventional procedures.
Clinical Trial Phases in Oncology
Phase I : Evaluates safety, pharmacokinetics, Maximum Tolerated Dose (MTD), and Dose-Limiting Toxicities (DLTs) in small patient cohorts.
Phase II : Evaluates therapeutic efficacy and safety for specific tumor types.
Phase III : Compares the investigational agent against standard-of-care therapy in large randomized controlled trials.
Phase IV : Post-marketing surveillance to monitor long-term safety and rare adverse events.
Standards of Informed Consent in Oncology
Informed consent is an ongoing communication process, not merely a signed document. Key elements of valid informed consent include:
- Full disclosure of diagnosis, disease stage, and natural disease progression without treatment
- Explanation of proposed treatment mechanisms, administration schedule, and expected benefits
- Comprehensive review of potential toxicities, short-term and long-term risks, and mortality risks
Discussion of reasonable alternative therapies (including standard-of-care, alternative trials, or palliative/hospice care)
Explicit affirmation of voluntary participation and the patient's right to withdraw consent at any time without compromising ongoing standard clinical care
- Provision of consent documents written in clear, plain language (target 6th to 8th-grade reading level)
- Quality Improvement (QI) & Patient Safety Methodologies
Quality improvement in oncology strives to enhance clinical outcomes, eliminate care delivery errors, and maintain alignment with national benchmarks.
ASCO Quality Oncology Practice Initiative (QOPI®)
The American Society of Clinical Oncology (ASCO) QOPI® program provides oncology practices with evidence-based performance measures. Key QOPI core quality metrics include:
Documentation of clinical staging prior to initiating antineoplastic therapy
Molecular biomarker testing prior to targeted therapy administration (e.g., HER2 in breast cancer, EGFR/ALK/ROS1 in NSCLC, BRAF in melanoma)
- Standardized assessment of pain and emesis at every clinical encounter
- Formal documentation of chemotherapy consent prior to cycle 1
- Timely referral and involvement of palliative care services
- Adherence to evidence-based antiemetic guidelines for high/moderate emetogenic chemotherapy
- Plan-Do-Study-Act (PDSA) Cycles
The PDSA cycle is an iterative four-stage model for continuous quality improvement:
Plan : Identify a clinical process flaw, formulate an objective, and plan an intervention.
Do : Implement the test intervention on a small pilot scale.
Study : Collect data, analyze results, and compare outcomes against pre-intervention baseline metrics.
Act : Adopt, adapt, or abandon the intervention based on data findings, then prepare for broader implementation.
Root Cause Analysis (RCA) vs. FMEA
When a sentinel event or near-miss medication error occurs (e.g., wrong-dose vincristine administration or intrathecal medication error), APRNs participate in structured safety analyses:
Root Cause Analysis (RCA) : A retrospective safety investigation designed to identify underlying latent systemic vulnerabilities (e.g., ambiguous EHR order entry screens, inadequate double-check workflows, staffing fatigue) rather than placing individual blame on clinicians. Common RCA tools include the 5 Whys technique and the Fishbone (Ishikawa) cause-and-effect diagram .
Failure Mode and Effects Analysis (FMEA) : A prospective risk management assessment conducted before implementing a new process to identify potential failure points and prevent harm.